The Effect of Education and Telephone Follow-up Given to Cancer Patients Receiving Immunotherapy on Symptom Management and Self-care Power

NCT05683652 | Unknown DMC

• 1 other identifier: E-84892257-300-100327
• Study Type: interventional
• Target: 56
• Locations: 1 country
• Sites: 1

Brief Summary

This study, it was aimed to evaluate the effects of education and telephone follow-up given to cancer patients receiving immunotherapy on symptom management and self-care power. It is expected that the education given to the patients who will receive immunotherapy for the first time and the monitoring by phone, prevention of immunotherapy-related side effects, early recognition, and follow-up will reduce unnecessary hospital admissions and increase the self-care power of the patient.

Conditions

Self Care; Symptom Management; Immunotherapy; Cancer Patient

Keywords

Immunotherapy; Symptom Management; Self care power

Outcome Measures

Primary Outcomes (5)

• Nightingale Symptom Rating Scale

  Nightingale Symptom Assessment Scale (N-SDS) is a quality of life scale developed by Gülbeyaz Can and Adnan Aydıner in 2009 for cancer patients. Consisting of 38 items in total, the scale (N-CSS) has three sub-dimensions: Physical Well-Being (Physician) (items 1-4, 6-15, 23-27 and 37), Social Well-Being (SoIH) (5 and Articles 16-22) and Psychological Well-Being (PSYH) (Articles 28-36 and 38). When each item in the scale is used alone, it can be reflected how the cancer patients who are planned to receive or receiving chemotherapy are affected by the disease/treatment-related problems. In this Likert-type scale, the answer given by the patient to the evaluated item is scored as "0", if it is very little, "1", if it is a little, "2", if it is quite a lot, "3", and if it is too much, it is scored as "4". A high score indicates that the level of being affected by the disease/treatment-related problems is high.

  In patients receiving immunotherapy, the first measurements will be made at the end of the 1st cycle (the cycle is 28 days)

• Demographic and Medical Characteristics - Patient Information Form

  It consists of a total of 8 questions created by the researcher after the literature review. 6 questions include medical characteristics, 2 questions include demographic characteristics.

  It will meet within 3 months with patients who agree to participate in the study.

• Telephone Interview Form

  atients who were given pre-immunotherapy training will be called after each cure and interviewed for symptom management. A telephone interview form was created by the researcher to record the interviews.

  Patients in the experimental group receiving immunotherapy will be followed up by phone for 3 months.

• Phone Call Evaluation Form

  A phone call evaluation form prepared by the researcher will be used to evaluate the phone calls made after each cure. It will be applied to the intervention group as a post-test.

  It will be applied to the patients in the experimental group as a result of 3-month follow-up.

• Self Care Power Scale

  The scale used to measure an individual's self-care ability or self-care power was developed by Kearney and Fleicher (1979) in English with 43 items, and is a 35-item shortened Turkish form. The scale focused on individuals' self-assessment of their involvement in self-care actions. Each statement is scored from 0 to 4. Individuals' orientation towards self-care is determined by participants' responses on a 5-point Likert-type scale. Among the answer options, "Doesn't describe me at all" is given 0 points, the others are given 1 point for "Doesn't describe me very well", 2 points for "I have no idea", 3 points for "Describes me a little", and 4 points for "Describes me a lot".In the Turkishized scale, 8 items (3, 6, 9, 13, 19, 22, 26 and 31) are evaluated as negative and the scoring is reversed. The maximum score is 140. The high score obtained from the scale indicates the high level of self-care or self-care ability and power of the individual. There is no limit/cut off value.

  The first measurements of the patients receiving immunotherapy will be done at the end of the 1st cycle (each cycle is 28 days)

Secondary Outcomes (2)

• Nightingale Symptom Rating Scale

  In patients receiving immunotherapy, the second measurements will be made at the end of the third cycle (the cycle is 28 days)

• Self Care Power Scale

  n patients receiving immunotherapy, the second measurements will be made at the end of the third cycle (the cycle is 28 days)

Interventions

TRAINING BOOKLET DEVICE

Cancer patients in the intervention group, who will receive immunotherapy for the first time, will be given face-to-face training with the prepared training booklet and followed up by phone. Patients who received immunotherapy after the 1st, 2nd and 3rd cycles, respectively, will be called by phone. The researcher's phone number will be given to the intervention group patients and they will be told that they can call 24/7 if they experience any symptoms. The telephone interview form created by the researcher will be used during the monitoring by telephone.

Also known as: Telephone follow up

Eligibility Criteria

• Age: 18 Years - 90 Years
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Ability to read and write in Turkish,
• Absence of any psychiatric disorder that will reduce the ability to comprehend and understand,
• Not having any physical discomfort in the area of hearing or speaking that would prevent telephone conversations,
• Will receive immunotherapy for the first time and only,
• Willingness to participate in the research,
• Willingness to participate in the research,
• Patients who agreed to participate in the study verbally and in writing were included in the study.

You may not qualify if:

• Not being voluntarily or willing to participate in the research,
• Will receive radiotherapy or chemotherapy together with immunotherapy,
• Not knowing that he will receive immunotherapy,
• Patients who did not accept to participate in the study were not included in the study.

Sponsors & Collaborators

• Ankara Medipol University: lead

Study Sites (1)

Ankara Medipol University

Ankara, Turkey (Türkiye)

RECRUITING

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer

Study Record Dates

• First Submitted: June 21, 2022
• First Posted: January 13, 2023
• Study Start: June 30, 2021
• Primary Completion: April 1, 2023
• Study Completion: April 1, 2023
• Last Updated: January 13, 2023

Record last verified: 2022-06

Locations

TU (1)